Evidence map›Paper›PMID 24505334›Full record

Trial reportPloS one2014

Field efficacy of Vectobac GR as a mosquito larvicide for the control of anopheline and culicine mosquitoes in natural habitats in Benin, West Africa.

Armel Djènontin, Cédric Pennetier, Barnabas Zogo, Koffi Bhonna Soukou, Marina Ole-Sangba, Martin Akogbéto, Fabrice Chandre, Rajpal Yadav, Vincent Corbel

Abstract readClinical Trial
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Larviciding to prevent malaria transmission.The Cochrane database of systematic reviews · 2019
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Armel DjènontinFaculté des Sciences et Techniques/MIVEGEC (IRD 224-CNRS 5290-UM1-UM2), Université d'Abomey Calavi/Centre de Recherche Entomologique de Cotonou (CREC), Cotonou, Bénin.
Cédric PennetierMIVEGEC (IRD 224-CNRS 5290-UM1-UM2), Centre de Recherche Entomologique de Cotonou (CREC), Cotonou, Bénin.
Barnabas ZogoMIVEGEC (IRD 224-CNRS 5290-UM1-UM2), Centre de Recherche Entomologique de Cotonou (CREC), Cotonou, Bénin.
Koffi Bhonna SoukouMIVEGEC (IRD 224-CNRS 5290-UM1-UM2), Centre de Recherche Entomologique de Cotonou (CREC), Cotonou, Bénin.
Marina Ole-SangbaMIVEGEC (IRD 224-CNRS 5290-UM1-UM2), Centre de Recherche Entomologique de Cotonou (CREC), Cotonou, Bénin.
Martin AkogbétoFaculté des Sciences et Techniques/Centre de Recherche Entomologique de Cotonou (CREC), Université d'Abomey Calavi/Centre de Recherche Entomologique de Cotonou (CREC), Cotonou, Bénin.
Fabrice ChandreMIVEGEC (IRD 224-CNRS 5290-UM1-UM2), Laboratoire de lutte contre les Insectes Nuisibles (LIN), Montpellier, France.
Rajpal YadavDepartment of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
Vincent CorbelMIVEGEC (IRD 224-CNRS 5290-UM1-UM2)/Department of Entomology, Kasetsart University, Ladyaow Chatuchak Bangkok, Thailand.

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionThe efficacy of Vectobac GR (potency 200 ITU/mg), a new formulation of bacterial larvicide Bacillus thuringiensis var. israelensis Strain AM65-52, was evaluated against Anopheles gambiae and Culex quinquefasciatus in simulated field and natural habitats in Benin.

methodsIn simulated field conditions, Vectobac GR formulation was tested at 3 dosages (0.6, 0.9, 1.2 g granules/m² against An. gambiae and 1, 1.5, 2 g granules/m² against Cx. quinquefasciatus) according to manufacturer's product label recommendations. The dosage giving optimum efficacy under simulated field conditions were evaluated in the field. The efficacy of Vectobac GR in terms of emergence inhibition in simulated field conditions and of reduction of larval and pupal densities in rice fields and urban cesspits was measured following WHO guidelines for testing and evaluation of mosquito larvicides.

resultsVectobac GR caused emergence inhibition of ≥80% until 21 [20]-[22] days for An. gambiae at 1.2 g/m² dose and 28 [27-29] days for Cx. quinquefasciatus at 2 g/m² in simulated field habitats. The efficacy of Vectobac GR in natural habitats was for 2 to 3 days against larvae and up to 10 days against pupae.

conclusionsTreatment with Vectobac GR caused complete control of immature mosquito within 2-3 days but did not show prolonged residual action. Larviciding can be an option for malaria and filariasis vector control particularly in managing pyrethroid-resistance in African malaria vectors. Since use of larvicides among several African countries is being emphasized through Economic Community of West Africa States, their epidemiological impact should be carefully investigated.

Indexed as

AnophelesBacillus thuringiensisCulexEcosystemInsect VectorsAnimalsBeninFilariasisLarvaMalariaPest Control, BiologicalTime Factors

Identifiers

PMID24505334
PMCPMC3914869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.